0001213900-22-057608.txt : 20220921
0001213900-22-057608.hdr.sgml : 20220921
20220921120934
ACCESSION NUMBER: 0001213900-22-057608
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210625
FILED AS OF DATE: 20220921
DATE AS OF CHANGE: 20220921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRUENER GARRETT
CENTRAL INDEX KEY: 0001106287
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54586
FILM NUMBER: 221255603
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER, SUITE 3700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NANOMIX Corp
CENTRAL INDEX KEY: 0001473579
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270801073
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 354 MERRIMACK STREET
STREET 2: #4
CITY: LAWRENCE
STATE: MA
ZIP: 01843
BUSINESS PHONE: (603) 935-9799
MAIL ADDRESS:
STREET 1: 354 MERRIMACK STREET
STREET 2: #4
CITY: LAWRENCE
STATE: MA
ZIP: 01843
FORMER COMPANY:
FORMER CONFORMED NAME: Boston Therapeutics, Inc.
DATE OF NAME CHANGE: 20101123
FORMER COMPANY:
FORMER CONFORMED NAME: AVANYX Therapeutics, Inc.
DATE OF NAME CHANGE: 20091001
4
1
ownership.xml
X0306
4
2021-06-25
0
0001473579
NANOMIX Corp
NNMX
0001106287
GRUENER GARRETT
C/O NANOMIX CORP.,
2121 WILLIAMS STREET
SAN LEANDRO
CA
94577
1
0
1
0
Common Stock
2022-03-02
4
C
0
25160338
A
25160338
D
Common Stock
2022-08-18
4
P
0
32
0.57
A
25160370
D
Common Stock
2022-08-19
4
P
0
2968
0.40
A
25163306
D
Common Stock
2022-08-22
4
P
0
1500
0.36
A
25174838
D
Common Stock
2022-08-22
4
P
0
11500
0.40
A
25176338
D
Senior Secured Convertible Promissory Note
0.0119
2021-06-25
4
J
0
1603778
1603778
A
2021-06-25
2023-06-25
Common Stock
134771261
1603778
D
Common Stock Purchase Warrants
0.0119
2021-06-25
4
J
0
134771261
A
2021-06-25
2026-06-25
Common Stock
134771261
134771261
D
Senior Secured Convertible Promissory Note
0.0119
2022-02-28
4
P
0
444444
444444
A
2022-02-28
2024-02-28
Common Stock
37348235
2048222
D
Common Stock Purchase Warrants
0.0119
2022-02-28
4
P
0
37348235
A
2022-02-28
2027-02-28
Common Stock
37348235
172119496
D
On June 25, 2021, Reporting Person exchanged a promissory note in the principal amount of $1,603,778 for (i) a senior secured convertible note for an aggregate principal amount of $1,603,778 (the "June 2021 Note") and (ii) a warrant to purchase 134,771,261 shares of the Issuer's common stock (the "June 2021 Warrant"). The June 2021 Note matures on June 25, 2023. The June 2021 Note is convertible at any time into shares of the Issuer's common stock equal to $0.0119 (the "Conversion Price"). The June 2021 Warrant is exercisable at any time into shares of common stock equal to $0.0119 (the "Exercise Price"). On March 2, 2022, the Conversion Price and Exercise Price were adjusted to $2.0587 upon consummation of the Issuer's previously announced reverse split. The Conversion Price and Exercise Price were again amended to $1.1717 in March 2022. At any time during any Event of Default, the Conversion Price in effect may be equal to the Alternative Conversion Price (as defined in the Note).
On February 28, 2022, Reporting Person was issued (i) a senior secured convertible note of the Issuer for an aggregate principal amount of $444,444 (the "February 2022 Note") and (ii) a warrant to purchase 37,348,235 shares of the Issuer's common stock (the "February 2022 Warrant") for an aggregate purchase price of $400,000. The February 2022 Note matures on February 28, 2024. The February 2022 Note is convertible at any time into shares of the Issuer's common stock at the Conversion Price. The June 2021 Warrant is exercisable at any time into shares of the Issuer's common stock at the Exercise Price. On March 2, 2022, the Conversion Price and Exercise Price were adjusted to $2.0587 upon consummation of the Issuer's previously announced reverse split. The Conversion Price and Exercise Price were again amended to $1.1717 in March 2022. At any time during the continuance of any Event of Default, the Conversion Price in effect may be equal to the Alternative Conversion Price.
On March 2, 2022, the Reporting Person's Series C Preferred Stock automatically converted into an aggregate of 25,160,338 shares of the Issuer's common stock upon consummation of the Issuer's previously announced reverse stock split.
/s/ Garrett Gruener
2022-09-21